RankAlpha logo
Back to Rankings

ALGS

Aligos TherapeuticsA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The post-earnings update was incrementally better than the April baseline: B-SUPREME remains active after clearing futility, the Amoytop transaction adds a $25 million upfront cash component, and management now guides runway into the fourth quarter of 2026 rather than only into the third quarter. That supports a monitoring thesis instead of a fresh deterioration call.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Management said current cash is expected to fund operations only into the fourth quarter of 2026, inclusive of the expected Amoytop upfront, leaving a financing or partnering need ahead of 2027 topline data [#8-K-2026-05-07].
Momentum
65
Value
57
Sentiment
64
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $5.80 · Bull $10.00 · Bear $3.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-02 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-09 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $68.20
Why
Momentum65 · Δ7d -
Value57 · Δ7d +0.1
Sentiment64 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
65
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
57
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.1
Sentiment
64
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 65.5 / Value 57.5 / Sentiment 63.5

Fundamentals (TTM)
As of 2026-06-02
Market Cap
$32.49M
Beta
2.67
Shares Out
6.15M
P/E (TTM) · Derived
-0.4
P/S (TTM)
19.56
P/FCF (TTM) · Derived
-0.59
Rev YoY
-41.6%
EPS YoY
+1.0%
Gross Margin
-
Op Margin
-3277.9%
Net Debt
-$56.78M
Current Ratio
4.70
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology